Clinical Trial Update: A Study of MRG002 in the Treatment of Patients With HER2-expressed Advanced Malignant Solid Tumors. [Phase 1, Phase 2]

View source ↗

Summary

A clinical trial update for MRG002 in HER2-expressed advanced malignant solid tumors across Phase 1 and Phase 2.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Malignant Solid Tumors

Drugs mentioned

• MRG002

Snippet

Sponsor: Shanghai Miracogen Inc. | Conditions: Advanced Malignant Solid Tumors | Phase 1, Phase 2 | Status: UNKNOWN